Lipoxin A₄ prevents the progression of de novo and established endometriosis in a mouse model by attenuating prostaglandin E₂ production and estrogen signaling

• Published in: PloS one Vol. 9; no. 2; p. e89742
• Main Authors: Kumar, Rajesh, Clerc, Anne-Catherine, Gori, Ilaria, Russell, Ronan, Pellegrini, Chiara, Govender, Lerisa, Wyss, Jean-Christophe, Golshayan, Dela, Canny, Geraldine O
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 24.02.2014; Public Library of Science (PLoS)
• Subjects: Analysis of Variance; Angiogenesis; Animals; Aromatase; Aromatase - metabolism; Attenuation; Biology; Biosynthetic Pathways - drug effects; Cyclooxygenase 2 - metabolism; Cyclooxygenase-2; Cytokines; Dinoprostone - biosynthesis; DNA Primers - genetics; Endocrinology; Endometriosis; Endometriosis - physiopathology; Endometriosis - prevention & control; Endometrium; Estrogens; Estrogens - metabolism; Female; Fertility; Gene expression; Growth factors; Gynecology; Hospitals; Immunohistochemistry; Infertility; Inflammation; Interleukin 6; Interleukin-1beta - metabolism; Interleukin-6 - metabolism; Kinases; Laboratories; Lesions; Lipoxin A4; Lipoxins - pharmacology; Matrix metalloproteinase; Medical research; Medicine; Metabolism; Metalloproteinase; Mice; Mice, Inbred C57BL; Obstetrics; Pain; Pathophysiology; Peritoneal fluid; Peritoneum; Prostaglandin E2; Real-Time Polymerase Chain Reaction; Rodents; Signal transduction; Signal Transduction - drug effects; Signaling; Surgery; Transforming growth factor; Transplants & implants; Tumor necrosis factor-TNF; Vascular endothelial growth factor; Vascular Endothelial Growth Factor A - metabolism; Switzerland
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0089742

Endometriosis, a leading cause of pelvic pain and infertility, is characterized by ectopic growth of endometrial-like tissue and affects approximately 176 million women worldwide. The pathophysiology involves inflammatory and angiogenic mediators as well as estrogen-mediated signaling and novel, improved therapeutics targeting these pathways are necessary. The aim of this study was to investigate mechanisms leading to the establishment and progression of endometriosis as well as the effect of local treatment with Lipoxin A4 (LXA₄), an anti-inflammatory and pro-resolving lipid mediator that we have recently characterized as an estrogen receptor agonist. LXA₄ treatment significantly reduced endometriotic lesion size and downregulated the pro-inflammatory cytokines IL-1β and IL-6, as well as the angiogenic factor VEGF. LXA₄ also inhibited COX-2 expression in both endometriotic lesions and peritoneal fluid cells, resulting in attenuated peritoneal fluid Prostaglandin E₂ (PGE₂) levels. Besides its anti-inflammatory effects, LXA₄ differentially regulated the expression and activity of the matrix remodeling enzyme matrix metalloproteinase (MMP)-9 as well as modulating transforming growth factor (TGF)-β isoform expression within endometriotic lesions and in peritoneal fluid cells. We also report for first time that LXA₄ attenuated aromatase expression, estrogen signaling and estrogen-regulated genes implicated in cellular proliferation in a mouse model of disease. These effects were observed both when LXA₄ was administered prior to disease induction and during established disease. Collectively, our findings highlight potential targets for the treatment of endometriosis and suggest a pleotropic effect of LXA₄ on disease progression, by attenuating pro-inflammatory and angiogenic mediators, matrix remodeling enzymes, estrogen metabolism and signaling, as well as downstream proliferative pathways.